Adenovirus 40 and 41 Antibodies Associated With Protection From Infection in a Bangladeshi Birth Cohort
Higher antibody reactivity to AdV PB was associated with improved Year 2 AdV 40/41 outcomes, elevating it as a promising vaccine or monoclonal antibody target.
Authors
- Jozelyn Pablo (ORCID: https://orcid.org/0000-0002-7286-7688)
- Andy Teng (ORCID: https://orcid.org/0000-0002-2088-2181)
- David Camerini (ORCID: https://orcid.org/0000-0001-9429-5951)
- William A. Petri (ORCID: https://orcid.org/0000-0002-7268-1218)
- Jennifer Hendrick (ORCID: https://orcid.org/0000-0001-7352-2596)
- Amit Oberai (ORCID: https://orcid.org/0009-0006-2384-8890)
- Joseph J. Campo (ORCID: https://orcid.org/0000-0002-8652-0917)
- Vu Huynh
- Z. Jennie (ORCID: https://orcid.org/0000-0002-5839-2882)
Institutions
- University of California, Irvine (US)
- University of Virginia Health System (US)
- Antigen Discovery (United States) (US)
- University of Virginia (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1093/infdis/jiaf558
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00